TrovaGene, Inc. (NASDAQ:TROV)

CAPS Rating: 4 out of 5

Results 1 - 6 of 6

Recs

0
Member Avatar MrMighty (97.08) Submitted: 5/15/2015 4:25:32 PM : Outperform Start Price: $10.70 TROV Score: -4.43

I think the story is pretty compelling. Diagnostic tests that use urine are way more convenient. This is coming at a time when these tests are more needed with an aging population.

Recs

0
Member Avatar ciabia (< 20) Submitted: 4/22/2015 9:23:13 PM : Outperform Start Price: $8.64 TROV Score: +17.50

non-invasive tests which have a huge market potentials. Issues with diagnostic reimbursement may cause issues, but upside seems very good.

Recs

0
Member Avatar tes1900 (< 20) Submitted: 4/22/2015 5:25:20 PM : Outperform Start Price: $8.64 TROV Score: +17.50

Everything I have read about it seem quite bullish

Recs

0
Member Avatar Aquest (58.34) Submitted: 2/18/2015 4:46:37 PM : Outperform Start Price: $5.00 TROV Score: +103.85

TROV is developing a method of detecting cancer through urinalysis. This has huge potential. Their tests will also help in determining how cancer treatments are working. All this while being non-invasive.

Recs

0
Member Avatar nancytroi (< 20) Submitted: 10/7/2013 11:40:15 AM : Outperform Start Price: $7.39 TROV Score: +12.30

New Diagnostic tests for cancer.

Recs

0
Member Avatar ctcarrigan33 (50.38) Submitted: 7/23/2013 12:14:52 PM : Outperform Start Price: $8.42 TROV Score: -3.90

Cheaper than blood tests or traditional tests, and their validation tests of the technology have been positive thus far

Results 1 - 6 of 6

Featured Broker Partners


Advertisement